SERPLULIMAB for Lung neoplasm malignant: Side Effects & Safety Data
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
There are 13 adverse event reports in the FDA FAERS database where SERPLULIMAB was used for Lung neoplasm malignant.
Most Reported Side Effects for SERPLULIMAB
| Side Effect | Reports | % | Deaths | Hosp. |
|---|---|---|---|---|
| Neutrophil count decreased | 19 | 13.9% | 2 | 13 |
| Platelet count decreased | 18 | 13.1% | 2 | 11 |
| Pneumonia | 17 | 12.4% | 7 | 10 |
| White blood cell count decreased | 17 | 12.4% | 1 | 13 |
| Anaemia | 15 | 11.0% | 0 | 6 |
| Myelosuppression | 13 | 9.5% | 5 | 3 |
| Neutropenia | 11 | 8.0% | 0 | 2 |
| Nausea | 10 | 7.3% | 0 | 1 |
| Thrombocytopenia | 10 | 7.3% | 2 | 2 |
| Off label use | 8 | 5.8% | 6 | 0 |
| Pneumonitis | 8 | 5.8% | 0 | 2 |
| Pyrexia | 8 | 5.8% | 3 | 2 |
| Rash | 8 | 5.8% | 0 | 0 |
| Alanine aminotransferase increased | 7 | 5.1% | 0 | 3 |
| Aspartate aminotransferase increased | 7 | 5.1% | 0 | 3 |
Other Indications for SERPLULIMAB
Non-small cell lung cancer (32)
Small cell lung cancer extensive stage (16)
Squamous cell carcinoma of lung (16)
Small cell lung cancer (6)
Other Drugs Used for Lung neoplasm malignant
ERLOTINIB (9,207)
OSIMERTINIB (4,754)
NIVOLUMAB (4,197)
PEMBROLIZUMAB (3,575)
CARBOPLATIN (3,487)
ALECTINIB (2,932)
PEMETREXED (2,422)
CRIZOTINIB (1,949)
BEVACIZUMAB (1,810)
PACLITAXEL (1,747)